Core Viewpoint - Yongsheng Medical (01612.HK) reported its strongest interim performance in four years, with a revenue increase of 18.1% to HKD 449 million for the six months ending June 30, 2025 [1] Financial Performance - The profit attributable to shareholders rose by 55.1% to HKD 51.6 million [1] - The net profit margin improved to 12.1%, up from 8.8% in the first half of 2024 [1] - Earnings per share increased by 55.3% to HKD 0.0803, compared to HKD 0.0517 in the first half of 2024 [1] Dividend Declaration - The board declared an interim dividend of HKD 0.024 per share, up from HKD 0.016 per share in the first half of 2024 [1] Revenue Drivers - The strong performance in the first half of 2025 was primarily driven by a 28.6% increase in revenue from the imaging disposable products segment [1] - The respiratory products segment showed a recovery in revenue, which was sufficient to offset the decline from the orthopedic rehabilitation devices segment [1] Gross Profit and Margin - Gross profit increased by 33.4% to HKD 159 million, supported by economies of scale, improved operational efficiency, and reduced inventory provisions [1] - Gross margin improved from 31.3% to 35.4% [1]
永胜医疗(01612.HK)中期公司拥有人应占溢利增加55.1%至5160万港元